Evidence map›Paper›PMID 41196357›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Structural basis for a potent human neutralizing antibody targeting a conserved epitope on the H7 hemagglutinin head.

Junxin Li, Min Wang, Yang Yang, Limin Zhang, Lvyan Liu, Wei Yang, Yun Peng, Xu Zhang, Bin Yuan, Qi Peng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Junxin Li *Shenzhen Key Laboratory of Human Antibody Engineering, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.ORCID 0000-0003-2564-6986
Min Wang *Strategic Pandemic Action and Research Center, Guangzhou National Laboratory, Guangzhou 510005, China.
Yang Yang *Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Limin Zhang *State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, China.
Lvyan LiuInstitute of Maternal and Child Medicine, Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518116, China.
Wei YangShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Yun PengShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Xu ZhangState Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0009-0009-1797-0816
Bin YuanState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
Qi PengStrategic Pandemic Action and Research Center, Guangzhou National Laboratory, Guangzhou 510005, China.
Xiaolu YangDepartment of Cancer Biology and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-6755-7725
Yixin ChenState Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0000-0002-9591-634X
George F GaoStrategic Pandemic Action and Research Center, Guangzhou National Laboratory, Guangzhou 510005, China.ORCID 0000-0002-3869-615X
Yi ShiStrategic Pandemic Action and Research Center, Guangzhou National Laboratory, Guangzhou 510005, China.ORCID 0000-0002-3053-2687
Xiaochun WanShenzhen Key Laboratory of Human Antibody Engineering, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.ORCID 0000-0003-3745-1860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zoonotic H7N9 avian influenza virus infection remains a global concern because of its pandemic potential. Therefore, developing effective antibodies and vaccines against H7N9 is vital for preventing and controlling major outbreaks. Here, we isolated a human

Indexed as

Antibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H7N9 SubtypeAnimalsCryoelectron MicroscopyFemaleHumansInfluenza, HumanMiceMice, Inbred BALB COrthomyxoviridae InfectionsAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza Viruscryo-EM structureH7 avian influenza virushemagglutinin headhuman antibody

Identifiers

PMID41196357
PMCPMC12625957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.